Closed · HR001121S0037 · CFDA 12.910 · Discretionary

Assessing Immune Memory (AIM)

Federal grant opportunity posted by DARPA - Biological Technologies Office, cataloged on Grants.gov.

Varies
Award range
Closed
Status
October 26, 2021
Close date
-
Expected awards

The verdict

Assessing Immune Memory (AIM) is a closed discretionary listing from DARPA - Biological Technologies Office that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 73 other opportunities from DARPA - Biological Technologies Office.

Varies
award range
Closed
application status
12.910
CFDA program
73
other opportunities from DARPA - Biological Technologies Office

Archived opportunity record

Assessing Immune Memory (AIM) is closed (last close October 26, 2021). Check the agency catalog for replacement NOFOs. DARPA - Biological Technologies Office still indexes 73 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed October 26, 2021

Posted Aug 20 Closes Oct 26

Instrument

Procurement Contract

Description

Military service members rely on effective vaccination for the prevention of communicable disease as well as to guard against biothreat exposure. Many current vaccines lack durability (i.e., do not provide effective protection over long periods of time), and there are multiple pathogens and threats that lack prophylactic options altogether. It is currently impossible to predict vaccine durability from early response profiles, largely owing to ignorance of mechanisms underlying immune memory as well as an inability to measure the cellular contributors that invoke long-lasting immune protection. Formation of immune memory is a complex physiological process characterized by a diverse array of cellular interactions and signaling processes. AIM seeks to develop a platform capability to predict immune memory informed by a systems-level view of the host response to vaccination and its mechanisms.

Catch-all / unrestricted eligibility mark · HR001121S0037

Grants.gov marks Assessing Immune Memory (AIM) with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Procurement Contract. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the DARPA - Biological Technologies Office book (44 peers, 59% of 74).

Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

BAA Coordinator AIM@darpa.mil

More from DARPA - Biological Technologies Office

What to do next

Assessing Immune Memory (AIM) is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.910 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants